{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:13:34Z","timestamp":1794050014012,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.radonc.2023.109492","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T05:04:18Z","timestamp":1674623058000},"page":"109492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial"],"prefix":"10.1016","volume":"181","author":[{"given":"Saskia A.","family":"Cooke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Reymen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte","family":"Fredberg Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M.T.","family":"Dieleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Lewensohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judi N.A.","family":"van Diessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Sikorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"van Elmpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne M.F.","family":"Damen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Jakob","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 S.A.","family":"Belderbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109492_b0005","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0010","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0015","doi-asserted-by":"crossref","unstructured":"Nestle U, Schimek-Jasch T, Kremp S, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21:581-592. doi:10.1016\/s1470-2045(20)30013-9.","DOI":"10.1016\/S1470-2045(20)30284-9"},{"key":"10.1016\/j.radonc.2023.109492_b0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0025","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ijrobp.2004.04.013","article-title":"Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer","volume":"60","author":"Rengan","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109492_b0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the radiation therapy oncology group","volume":"82","author":"Machtay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109492_b0035","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-16-3277","article-title":"Modeling the cellular response of lung cancer to radiation therapy for a broad range of fractionation schedules","volume":"23","author":"Jeong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.109492_b0040","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.radonc.2009.03.006","article-title":"Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan","volume":"91","author":"Aerts","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0045","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2967\/jnumed.114.144253","article-title":"Areas of high 18F-FDG uptake on preradiotherapy PET\/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer","volume":"56","author":"Calais","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2023.109492_b0050","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ijrobp.2007.11.049","article-title":"Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study","volume":"71","author":"Aerts","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109492_b0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2012.03.005","article-title":"The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer","volume":"104","author":"van Elmpt","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.radonc.2016.02.008","article-title":"Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy","volume":"118","author":"van Diessen","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0065","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1007\/s00259-008-0874-2","article-title":"The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials","volume":"35","author":"Boellaard","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2023.109492_b0070","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A\u2019Hern","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.radonc.2023.109492_b0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2006.09.005","article-title":"Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972\u201322973)","volume":"43","author":"Belderbos","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.109492_b0080","doi-asserted-by":"crossref","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.radonc.2023.109492_b0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","article-title":"The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)","volume":"131","author":"van Diessen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0090","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0095","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0100","doi-asserted-by":"crossref","unstructured":"Kong FMS, Hu C, ten Haken R, et al. NRG-RTOG 1106\/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC\u2014Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation). Journal of Clinical Oncology. 2021;39:8548-8548. doi:10.1200\/JCO.2021.39.15_suppl.8548.","DOI":"10.1200\/JCO.2021.39.15_suppl.8548"},{"key":"10.1016\/j.radonc.2023.109492_b0105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2005.03.037","article-title":"Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the radiation therapy oncology group (RTOG) experience","volume":"63","author":"Machtay","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109492_b0110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.radonc.2009.06.004","article-title":"Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? a hypothesis-generating study","volume":"93","author":"de Ruysscher","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.radonc.2020.07.030","article-title":"Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: a systematic review and meta-analysis","volume":"151","author":"van Laar","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0120","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1158\/1078-0432.CCR-19-2627","article-title":"Modeling the impact of cardiopulmonary irradiation on overall survival in NRG oncology trial RTOG 0617","volume":"26","author":"Thor","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.109492_b0125","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jtho.2016.12.021","article-title":"Long-term results of a trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer: NCCTG N0028 (Alliance)","volume":"12","author":"Schild","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0130","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0135","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial\u2014a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0140","doi-asserted-by":"crossref","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. Journal of Clinical Oncology. 2021;39:8511-8511. doi:10.1200\/JCO.2021.39.15_suppl.8511.","DOI":"10.1200\/JCO.2021.39.15_suppl.8511"},{"key":"10.1016\/j.radonc.2023.109492_b0145","doi-asserted-by":"crossref","unstructured":"Buchwald ZS, Wynne J, Nasti TH, et al. Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation. Front Oncol. 2018;8. doi:10.3389\/fonc.2018.00612.","DOI":"10.3389\/fonc.2018.00612"},{"key":"10.1016\/j.radonc.2023.109492_b0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/pcmedi\/pbz004","article-title":"Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges","volume":"2","author":"Yang","year":"2019","journal-title":"Precis Clin Med"},{"key":"10.1016\/j.radonc.2023.109492_b0155","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0160","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109492_b0165","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/cancers13061222","article-title":"Molecular and clinical premises for the combination therapy consisting of radiochemotherapy and immunotherapy in non-small cell lung cancer patients","volume":"13","author":"Fr\u0105k","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.109492_b0170","doi-asserted-by":"crossref","unstructured":"Frakulli R, Salvi F, Balestrini D, et al. Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2017;6:S1-S7. doi:10.21037\/tlcr.2017.10.01.","DOI":"10.21037\/tlcr.2017.10.01"},{"key":"10.1016\/j.radonc.2023.109492_b0175","doi-asserted-by":"crossref","unstructured":"Roy SF, Louie A v., Liberman M, Wong P, Bahig H. Pathologic response after modern radiotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2019;8:S124-S134. doi:10.21037\/tlcr.2019.09.05.","DOI":"10.21037\/tlcr.2019.09.05"},{"key":"10.1016\/j.radonc.2023.109492_b0180","doi-asserted-by":"crossref","first-page":"689","DOI":"10.21037\/tlcr.2017.09.02","article-title":"Magnetic resonance imaging in precision radiation therapy for lung cancer","volume":"6","author":"Bainbridge","year":"2017","journal-title":"Transl Lung Cancer Res"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:24:51Z","timestamp":1759123491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":36,"alternative-id":["S0167814023000300"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109492","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109492"}}